549 results about "Osteocyte" patented technology

The invention belongs to the technical field of hydrogel, and relates to piezoelectric / conductive integrated hydrogel for jaw defect repair, which is prepared from methylacryloyl protein, zwitterionic monomer and titanate piezoelectric particles through ultraviolet crosslinking under the action of a crosslinking agent and a photoinitiator, the hydrogel comprises, by mass, 1.0%-10% of methacrylated protein, 1.0%-10% of zwitterionic monomers, 1.0%-10% of titanate piezoelectric particles and 0.1%-5% of an initiator, and the volume fraction of an accelerant is 0.05%-1.0%. The hydrogel disclosed by the invention has excellent mechanical strength and certain flexibility, can realize piezoelectric and conductive functions of the hydrogel, can effectively promote proliferation, differentiation and mineralization of bone cells under the action of an electric field, accelerates bone tissue repair, and has a more remarkable bone regeneration effect compared with a non-electrical stimulation material in the prior art.

The invention belongs to the technical field of microbial fermentation, and particularly relates to lactobacillus rhamnosus capable of maintaining bone health and improving local joint inflammation and a metagen and application of the lactobacillus rhamnosus. According to the invention, the probiotic NKU ML1-2 is subjected to fermentation culture, such that a post-generation product is prepared. Results of embodiments prove that the metagen product can enhance the oxidation resistance of cartilage and osteoblasts and promote the synthesis of anti-inflammatory factors and cartilage matrixes (type II collagen and proteoglycan), and has the potential of relieving oxidative stress and inflammatory response of local joints, relieving joint inflammation and delaying cartilage destruction. The prepared metagen product is high in safety and good in stability, and can be applied to preparation of medicines for preventing and / or treating osteoarthritis; the metagen product can also be used for promoting bone health, enhancing the antioxidant capacity of osteoblasts and / or chondrocytes, promoting osteoblast activity and / or promoting calcium absorption and fixation, and a new solution is provided for joint health management.

The invention provides an application of bifidobacterium animalis subsp. Lactis CP-9 in preparation of a product for promoting bone growth and development or improving bone health. Long-term research and a large number of experiments show that the bifidobacterium animalis subsp. Lactis CP-9 can improve the bone volume fraction, the bone trabecula thickness, the bone density and the bone volume of an organism, and can also effectively improve the growth hormone level and the insulin-like growth factor 1 level, so that bone growth and development are promoted. Meanwhile, the bifidobacterium animalis subsp. Lactis CP-9 can effectively improve the N-terminal propeptide level, osteocalcin level, bone morphogenetic protein level and osteoprotectin level of I-type procollagen in a body, and remarkably reduce the amino-terminal peptide level of the I-type collagen and the ligand level of nuclear factor kappa B receptor activating factor, so that osteoblast differentiation is promoted, osteoclast differentiation is inhibited, and osteoclast differentiation is inhibited. Furthermore, bone formation is promoted, bone resorption is inhibited, bone metabolism is improved, and finally the effect of improving bone health is achieved.

The invention discloses a method and a device for acquiring parameters of an internal fracture fixation system, and relates to the technical field of medical data processing. Constructing a digital model of the skeleton and the surrounding soft tissue based on the three-dimensional scanning image by utilizing a biomechanical principle; using a machine learning algorithm to train the historical case data, and generating a preliminary internal fixed parameter prediction model; applying the preliminary parameters to a digital model for simulation verification, and optimizing the internal fixed parameters to an optimal combination; performing personalized adjustment on the simulation result according to individual differences of patients and experience of clinical doctors; the state of the internal fixation system is monitored in real time in the operation process, and parameter fine adjustment is conducted according to feedback; the fracture healing condition is regularly evaluated after the operation, and the internal fixation parameters are adjusted according to the evaluation result. Through personalized and precise internal fixation parameter setting, a good mechanical repair environment is created for a fracture part, bone cell proliferation and ordered growth of callus are promoted, and the healing time is effectively shortened.

A method for constructing a microfluidic bone organoid-on-chip can continuously observe the impacts of different external factors on a bone tissue structure based on the “ternary regulation theory” of bone angiogenesis-bone resorption-osteogenesis coupling. The method includes: (1) building a visual three-dimensional cell cultivation platform to continuously observe impacts of different external factors on a ternary regulation theory based on angiogenesis of osteoclast precursors, osteoblasts and osteoclasts, such that a user is allowed to directly observe interactions among various kinds of cells; (2) designing microfluidic channels in a chip to allow a reagent involved to present a concentration gradient distribution in the chip; and (3) adding three bioinks including osteoblasts, osteoclasts and vascular endothelial cells respectively, so as to reflect the three cell components individually, in pairs, and as a whole in the chip. An apparatus for constructing a microfluidic bone organoid-on-chip is further provided.

The invention discloses combined lactobacillus salivarius CCFM1327 capable of inhibiting foaming of macrophages and relieving periodontitis, and belongs to the technical field of microorganisms. According to the invention, the strain of combined lactobacillus salivarius CCFM1327 is obtained, and the combined lactobacillus salivarius has the effects of inhibiting foaming of macrophages and relieving periodontitis, which are specifically reflected in that the combined lactobacillus salivarius can inhibit foaming of RAW264.7 cells caused by ox-LDL; the growth of porphyromonas gingivalis can be effectively inhibited; the periodontal probing and diagnosing depth of the periodontitis rats can be obviously reduced; the number of pathogenic bacteria in the oral cavity of the periodontitis rat is reduced; the level of an inflammatory factor IL-17A in serum is reduced; alveolar bone loss of rats suffering from periodontitis is reduced; and the number of alveolar bone osteoclasts is reduced.

The invention belongs to the field of medicines, and particularly relates to application of a new target NCSTN for regulating and controlling bone metabolism and an agonist of the new target NCSTN in preparation of a medicine for preventing or treating osteoporosis. The invention aims to provide a new target NCSTN for regulating and controlling bone metabolism and application of the new target NCSTN in promoting osteogenic activity, inhibiting osteoclast activity and treating osteoporosis. According to the invention, the mechanism of the NCSTN agonist for treating osteoporosis is found for the first time, and the NCSTN agonist has the effects of inhibiting osteoclast maturation and differentiation and promoting osteoblast bone formation function. The mechanism is greatly different from the previously reported mechanism of singly inhibiting bone resorption or singly promoting bone formation, and the osteoporosis treatment which simultaneously acts on bone resorption and bone formation can greatly reduce the adverse reaction of the body to the medicine.

The invention relates to an application of a CTHRC1 inhibitor in preparation of a medicine for preventing and / or treating arthritis. Specifically, the invention provides application of an inhibitor or an antagonist of a CTHRC1 gene or a protein thereof, the inhibitor or the antagonist is used for preparing a composition or a preparation, and the composition or the preparation is used for (a) preventing and / or treating arthritis-related diseases; and / or (b) inhibiting cartilage cell senescence.

The invention discloses a yak bone collagen peptide for improving osteoporosis and preparation and application thereof, and relates to the field of biological medicine, the yak bone collagen peptide comprises collagen peptide with the molecular weight of 500-2000 Daltons, contains a glycine-proline-hydroxyproline tripeptide core structure, can promote osteoblast differentiation and inhibit osteoclast activity, and can be used for treating osteoporosis. The amino acid sequence of the collagen peptide is any one of the following sequences: glycine-proline-hydroxyproline-glycine-glutamic acid-arginine, and the amino acid sequence of the collagen peptide is any one of the following sequences: glycine-proline-hydroxyproline-glycine-glutamic acid-arginine; and the amino acid is glycine, proline, hydroxyproline, serine, leucine and alanine. The yak bone collagen peptide has a unique glycine-proline-hydroxyproline tripeptide structure, the molecular weight is controlled within the range of 500-2000 Daltons, the structure can promote osteoblast differentiation and inhibit osteoclast activity at the same time, and the problem that a traditional osteoporosis treatment medicine is single in function is solved.

The invention discloses a method for inducing osteoblasts by using mesenchymal stem cells, and belongs to the technical field of biology. The method for inducing the osteoblasts comprises the step of adding brucella outer membrane protein into a conventional osteoblast induction culture medium to promote the dental pulp stem cells to be differentiated into the osteoblasts. According to osteoblast differentiation metaphase differentiation marker detection, the cell ALP activity of a group added with 800ng / mL of brucella outer membrane protein is 2.36 times that of a conventional osteoblast induction culture medium group; according to osteoblast differentiation end-stage differentiation marker detection, the calcium deposition amount of brucella outer membrane proteome cells added with 800ng / mL is 481.54 mu g / mg protein, and is 2.55 times of that of a conventional osteoblast induction culture medium group. By adding the brucella outer membrane protein into a conventional osteoblast induction culture medium, the osteogenic differentiation efficiency of the dental pulp stem cells can be effectively improved.

The invention discloses an electroactive dressing used for promoting bone cell differentiation and bone regeneration and used for negative pressure therapy and a manufacturing method. The manufacturing method of the electroactive dressing comprises the steps that S1, a PLLA / BG spinning solution is prepared; s2, preparing a PLLA / BG nanofiber membrane through electrostatic spinning; s3, vacuum drying; s4, PAMAM-NH2 surface modification, the negative pressure treatment dressing relates to the technical field of negative pressure treatment dressings, when mechanical deformation is generated during negative pressure work, the piezoelectric biological film generates continuous electric stimulation, and the electric stimulation has positive and beneficial effects on osteoblasts and bone tissue physiological processes. The generated electric effect continuously collects functional electrolyte in surrounding tissues, and the functional electrolyte is separated in the wound by the dendrimer PAMAM-NH2, so that excessive exudation caused by negative pressure treatment is effectively made up. Meanwhile, the flow of the electrolyte further strengthens a local electric signal, so that cell migration and osteoblast proliferation and differentiation are effectively promoted.

The present invention relates to a nanomaterial for preventing tumor bone metastasis, a preparation method therefor, and use thereof. The present invention has discovered a spatiotemporal coupling interaction between tumor cells and osteoclasts, and provides a tumor-bone initial metastasis behavior-targeting strategy which can accurately prevent tumor metastasis on the basis of the source, and can avoid drug resistance and biochemical drug resistance. On this basis, the present invention designs a physical killing nanomaterial targeting tumor-osteoclast conjugates, the nanomaterial being a bone targeting group-modified nanovesicle encapsulating a carbonate compound and a phosphate compound. The nanomaterial can be effectively concentrated in bone tissue; when tumor cells are activated, the acid secretion function of tumor-related osteoclasts in nearby tumor-osteoclast conjugates which are in contact with the tumor cells triggers the carbonate compound to generate carbon dioxide gas and promotes the release of the phosphate compound, which forms calcium phosphate crystals with calcium ions so as to kill nearby tumor cells, thus achieving a specific very-early tumor metastasis inhibition effect.

The invention discloses a gelatin-hyaluronic acid injectable hydrogel drug-carrying nanoparticle composite material as well as a preparation method and application thereof, relates to the technical field of biomedicine, and solves the problems that in the prior art, existing drugs for treating cartilage related diseases are difficult to deliver; the chronic inflammatory response in the articular cavity cannot be effectively controlled and cartilage cells cannot be protected at the same time, so that the application effect of the medicine is limited. The preparation method disclosed by the invention comprises the following steps: S1, obtaining a carnosine modified hyaluronic acid derivative Car-HA; s2, preparing nano particles (FNPs) loaded with fenofibrate; and S3, mixing the gelatin solution containing the FNPs with a Car-HA solution, adding transglutaminase into the mixed system, and carrying out an enzymatic cross-linking reaction to form the hydrogel FNPs-GelHA with a stable network structure. The CarHA and FNPs synergistic hydrogel strategy provided by the invention has good structural adjustability and drug adaptability, is suitable for delivery of various anti-inflammatory, anti-oxidation and cartilage repair drugs, and can be widely applied to local precise treatment of cartilage related diseases.

The invention provides modified milk powder capable of promoting bone health as well as a preparation method and application of the modified milk powder. The total protein content of the modified milk powder is 17-35 g / 100 g, the fat content of the modified milk powder is 1-32 g / 100 g, and the calcium content of the modified milk powder is 0.8-2.1 g / 100 g. Moreover, the modified milk powder contains bovine coloctrum and lactoferrin, the mass ratio of the bovine coloctrum to the lactoferrin is (5-100): 1 on the basis of the dry matter content, and the content of the lactoferrin in the modified milk powder is 2-400 mg / 100 g. The bovine colostrum and the lactoferrin are combined for preparing the milk powder, have a synergistic effect on promoting osteoblasts and inhibiting osteoclast proliferation, and are beneficial to bone health.

The invention discloses a bifidobacterium animalis subsp. Lactis BA-C53 and an application of the bifidobacterium animalis subsp. Lactis BA-C53 in products for improving bone health. The bifidobacterium animalis subsp. Lactis BA-C53 is classified and named as bifidobacterium animalis subsp. Lactis Bifidobacterium animalis subsp. Lactis BA-C53, the preservation number is CCTCC NO: M 2024460, the preservation unit is China Center for Type Culture Collection, and the preservation time is March 11, 2024. The bifidobacterium animalis subsp. Lactis BA-C53 can effectively improve the steady state of intestinal flora of a mouse with osteoporosis induced by estrogen deficiency, so that the relative abundance of phylum firmicalis and phylum actinomycetes is increased, the relative abundance of phylum bacteroides is reduced, and then short-chain fatty acid is generated to activate intestinal immunity and maintain the integrity of an intestinal barrier, so that the osteoporosis caused by estrogen deficiency is inhibited. Meanwhile, osteoclast differentiation can be inhibited by regulating NFATC1, RANKL and OPG pathways, then osteoporosis is relieved, and the compound can be widely applied to preparation of food and drugs.

The invention provides a Falcarindiol derivative, preparation thereof and application of the Falcarindiol derivative in preparation of medicines for preventing and / or treating bone diseases. The structural general formula of the Falcarindiol derivative is as shown in formula I in the specification. Experimental results show that the Falcarindiol derivative can significantly inhibit osteoclast differentiation, and is expected to be used for preparing novel drugs for preventing and / or treating osteoporosis, osteoporosis fracture, osteolysis, periprosthetic osteolysis, tumor bone metastasis, inflammatory bone loss, periodontitis inflammatory bone resorption and other bone diseases. # imgabs0 #

The invention relates to a diatomic iron-iron site nano-enzyme constructed by relieving oxidative stress and cartilage degeneration and used for targeted osteoarthritis treatment. According to the invention, a nitrogen-doped porous carbon anchored diatomic iron nano enzyme catalyst (Fe2-NCs) with Fe-Fe dimer coordination is developed by using a'subject-object 'strategy. The Fe2-NCs protect cartilage cells from oxidative stress induced apoptosis by modulating ROS and active nitrogen species (RNS) and promoting O2 release. In addition, Fe2-NCs restores mitochondrial function by inhibiting NOX4 expression, improving ATP production, and normalizing COXIV levels. In an in-vivo OA model, the Fe2-NCs can reduce the expression of a pro-inflammatory medium COX-2 through an NF-kappa B signal channel, inhibit the up-regulation of MMP-13 and delay the degradation of type II collagen. The invention provides a new theoretical framework and methodological approach for the treatment of osteoarthritis, and has important clinical and scientific significance.

The invention discloses an eggshell membrane peptide for enhancing bone mineral density as well as a preparation method and application thereof, belongs to the technical field of egg by-product processing, and particularly relates to a preparation method of the eggshell membrane peptide for enhancing bone mineral density, which comprises the following steps: carrying out vacuum freeze drying and crushing on an eggshell membrane to obtain eggshell membrane powder; mixing the eggshell membrane powder with deionized water to obtain an eggshell membrane solution; adding keratinase, performing enzymolysis, and taking supernate; adding collagenase, carrying out enzymolysis, and centrifuging to take supernate, so as to obtain primary enzymatic hydrolysate; adding alkaline phosphatase, performing enzymolysis and centrifugation, and taking supernate to obtain enzymatic hydrolysate; and performing ultrafiltration and drying to obtain the eggshell membrane peptide. According to the eggshell membrane peptide for enhancing the bone mineral density, keratin cross-linking is destroyed through enzymolysis of keratinase, active peptide capable of stimulating osteoblast proliferation is released through enzymolysis of collagenase, phosphopeptide calcium binding sites are further activated through enzymolysis of alkaline phosphatase, calcium salt deposition is promoted, and the eggshell membrane peptide for enhancing the bone mineral density is provided.

The invention belongs to the technical field of medical treatment, and discloses an osteoarthritis rehabilitation auxiliary device and system, and the device comprises an intelligent vibration treatment module, a pressure sensor and biological feedback module, an intelligent control and APP remote management module, a pressure sensor, an accelerometer, and a myoelectricity sensor. The joint pain is relieved, vibration can stimulate sensory nerves, pain signal transmission is reduced, and the pain degree is reduced. Vibration promotes secretion of joint fluid, friction is reduced, and the range of motion is improved. Low-frequency vibration stimulates the activity of cartilage cells, and cartilage degeneration is slowed down. And a biological feedback system is intelligently regulated and controlled, so that the treatment accuracy is improved. Non-invasive treatment is achieved, and no side effect exists; gastrointestinal discomfort caused by drug treatment or high cost of long-term physical treatment is avoided. Remote monitoring is achieved, compliance is improved, a patient can be treated at home and does not need to see a doctor frequently, and medical cost is reduced.

The invention relates to application of an oroxylum indicum flavone extract in tumor-induced bone destruction, and relates to the field of biological medicines. The oroxylum indicum flavone extract comprises at least one of oroxylum indicum A and oroxylum indicum B, can inhibit tumor-induced osteoclast generation, can be used as a tumor-induced osteoclast differentiation inhibitor drug, and is used for treating tumor-induced bone destruction osteoclast activity abnormity diseases.

The invention relates to the technical field of recombinant proteins, and relates to a recombinant XII type collagen as well as a preparation method and application thereof. The recombinant XII type collagen is formed by connecting 5-30 repetitive units in series, and the amino acid sequence of each repetitive unit is as shown in SEQ ID NO: 1. The nucleic acid molecule is used for coding the recombinant XII type collagen; a vector comprises the nucleic acid molecule. According to the invention, a nucleotide sequence for coding the amino acid sequence is inserted into a vector to obtain a recombinant plasmid vector, then the recombinant plasmid vector is introduced into a host cell for culture, and then separation and purification are carried out to obtain the recombinant XII type collagen. The recombinant XII type collagen provided by the invention is easy to obtain, can realize efficient secretory expression, and meets the requirements of industrial production; the biological activity is good, and the proliferation and migration of human immortalized cartilage cells can be promoted.

The invention provides a construction method and application of a transgenic animal model with osteoclast specific deletion, and belongs to the technical field of gene engineering. The invention provides a method for constructing an animal model of an osteoclast expression diphtheria toxin receptor, and particularly provides a method for constructing the animal model of the osteoclast expression diphtheria toxin receptor by using a Cre-loxP method. According to the method, the diphtheria toxin receptor is specifically expressed in the osteoclast, and the osteoclast can be specifically deleted by injecting the diphtheria toxin. The animal model of the osteoclast expression diphtheria toxin receptor prepared by the method can stably inherit after being established, is economical and reliable, can provide important theoretical and practical guidance for bone tumor treatment, also provides powerful animal model support for research of bone tumor growth correlation, and has a wide application prospect. Technical conditions are provided for screening, developing, preventing or treating medicines for bone tumors.

The application discloses a flavonoid compound in eaglewood as well as a preparation method and application of the flavonoid compound, and relates to the technical field of medicines. The application extracts and separates a new compound from natural eaglewood, and the new compound is used in the preparation of anti-osteoporosis drugs. The compound is detected in vitro to obtain an induction effect of the compound on the differentiation of bone marrow mesenchymal stem cells (BMSCs) into osteoblasts, so as to affect the formation of osteoclasts. Meanwhile, the compound can promote the bone development of zebra fish through RT-qPCR detection, which indicates that the compound has anti-osteoporosis activity. The separation method of the compound is simple and easy to operate.

The invention belongs to the field of medicine, and discloses application of POCM-NP-coated A939572 in preparation of a medicine for treating osteoporosis, the POCM-NP-coated A939572 comprises osteoclast precursor cell membrane vesicles and NP-coated A939572 loaded on the osteoclast precursor cell membrane vesicles, and the NP-coated A939572 is PLGA (poly (lactic-co-glycolic acid)) nanoparticles entrapped with the NP-coated A939572. The POCM-NP-coated A939572 obtained by loading the nanoparticles loaded with the A939572 small molecule medicine into the osteoclast precursor cell membrane vesicles has the effect of relieving the osteoporosis, can inhibit osteoclast differentiation and can be used for preventing, treating and relieving the osteoporosis.

The invention provides a polyketone compound and application thereof in preparation of an osteoclast differentiation inhibitor, and relates to the technical field of marine natural products. The compound is obtained by separation and purification from a fermentation culture of a marine fungus talaromyces sp. GMIMD 02524 (the preservation number is GDMCC No. 66968), the compound is named as talaromyces furanone A, and the structure of the compound is as shown in the formula (I) in the specification. The compound can effectively inhibit RANKL-induced osteoclast differentiation by inhibiting an NF-kappa B signal channel in vitro, and has no obvious cytotoxicity at an effective concentration. Therefore, the compound talaromyfuranone A can be used for developing medicines for preventing and treating osteoclast-related osteolytic diseases such as osteoporosis and the like, and has a good application prospect.

The invention provides application of polypeptide or related biological materials thereof in inhibition of osteoclast differentiation. The polypeptide with the amino acid sequence as shown in SEQ ID NO: 1 or related biological materials thereof can remarkably inhibit osteoclast differentiation, further effectively treat and / or prevent osteoporosis and is suitable for preparing products for treating and / or preventing osteoporosis.

The invention discloses application of a Trim3 gene and / or an expression product thereof in preparation of medicines for treating osteoporosis. The over-expression of the Trim3 can improve the bone mineral density of osteoporosis model mice, inhibit bone resorption, inhibit osteoclast differentiation and inflammatory response in vitro, improve osteoporosis and provide a new target for diagnosis and treatment of osteoporosis.

The invention relates to the technical field of biological medicine, in particular to I-type humanized collagen as well as a preparation method and application thereof. The amino acid sequence of the type I humanized collagen prepared by the invention is shown as a sequence SEQ ID NO. 1 (HTGAWGKTVIEYKTTKTSRLVMGFXGPKGAA, wherein X is hydroxyproline). The invention also discloses a preparation method of the type I humanized collagen. The I-type humanized collagen contains essential amino acids and semi-essential amino acids of a human body, promotes proliferation of human skin fibroblasts, up-regulates expression of elastin, fibronectin and collagen I genes, and has the effects of interacting with endothelial cells and osteoblasts, promoting creeping and growth of the osteoblasts, and promoting the growth of the osteoblasts. And the interaction between osteoblasts and collagen is promoted. Therefore, the I-type humanized collagen can be widely applied to orthopedic sports materials and has application prospects in the fields of medical cosmetology and sports medicine materials.

The invention discloses a tetrahydro-beta-carboline compound as well as a preparation method and application thereof. The tetrahydro-beta-carboline compound is shown as a formula P. The tetrahydro-beta-carboline compound has good RANKL inhibitory activity, the preparation method is simple, raw materials are easy to obtain, and the yield is high. The inhibition activity of the compound on generation of RANKL-induced osteoclasts is determined through a tartrate acid phosphatase (TRAP) staining experiment, it is determined through a surface plasmon resonance (SPR) that the compound has high combining capacity with RANKL protein, and the compound can be used for preparing drugs for preventing and / or treating diseases caused by abnormal osteoclast activity. # imgabs0 #

The invention discloses application of a compound with a benzo-aza structure in preparation of a medicine for inhibiting osteoclast formation, the structure of the compound is shown as a formula (1), and R substituent is one of H, OCH3, Br, F and i-Pr. Cell experiments prove that the compound with the benzo-aza structure has a remarkable inhibiting effect on RANKL-induced osteoclast differentiation and marker gene expression, can be used as a candidate medicine which is novel in structure and is used for inhibiting osteoclast formation, and is used for targeting osteoclast to treat osteoporosis related diseases.